Medical News

RSS

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.

23 Feb 2010

Findings suggest bitter melon extract may help in preventing breast cancer

Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study.

23 Feb 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

Government, with billions in loans, bets electronic medical records can improve care

The New York Times reports that electronic health records hold potential for major improvements in health outcomes for patients as the federal government puts a renewed emphasis on implementing and digitizing patients' information. "President Obama's economic stimulus included $19.2 billion for health information technology, and a number of hospital systems around the country are taking advantage of this financial incentive and investing their own money to foster the creation and use of electronic records that are expected to improve the quality, efficiency and safety of medical care."

23 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Blair talks about combating malaria in Nigeria, part of 3-nation African trip

"Former British prime minister Tony Blair on Saturday called for concerted efforts to combat malaria in Nigeria which accounts for a quarter of the [nearly] one million malaria deaths annually in Africa," Agence France-Presse writes (2/20).

23 Feb 2010

Jobs bill missing Medicaid money for states, governors call for change

The $15 billion jobs bill that passed the Senate Monday does not include additional matching funds for state Medicaid programs, but governors are continuing to ask for its inclusion as they look for other ways to plus state budget holes made from Medicaid liabilities.

23 Feb 2010

Timely treatment and rehabilitation key to proper healing

Sometimes athletes can be their own worst enemy especially when they continue to play following an injury to a foot or ankle. Surgeons presenting at the Annual Scientific Conference of the American College of Foot and Ankle Surgeons (ACFAS) today are discussing athletic injuries and the importance of proper diagnosis, prompt treatment, and full healing and rehabilitation.

23 Feb 2010

Elevated cerebrospinal fluid levels of P-tau231 may be an early diagnostic biomarker for Alzheimer's disease

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer's disease, may be an early diagnostic biomarker for Alzheimer's disease in healthy adults.

23 Feb 2010

EHSI: Health stocks gain after federal decision on payments

Emerging Healthcare Solutions, Inc. voiced encouragement from the climb of healthcare stocks on Monday after a federal announcement on Medicare payment rates - helping offset any worries about a White House proposal to regulate premiums.

23 Feb 2010

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.

23 Feb 2010

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Diagnostic Hybrids, a Quidel Company has received emergency use authorization from the U.S. Food and Drug Administration for its D3® UltraTM 2009 H1N1 Influenza A Virus ID Kit, a monoclonal antibody fluorescent staining kit for the specific identification of 2009 H1N1 influenza A in direct patient specimens or incubated tissue cultures.

23 Feb 2010

New Barts Cancer Research UK Centre launched

A new cancer centre, launched today, puts London at the forefront of cancer research.

23 Feb 2010

Trial for lawsuit against Anthem Blue Cross begins in California

The insurer "refused to pay for" customer Ephram Nehme "to get a liver transplant in Indiana because the company wanted to save money, a lawyer for the patient told jurors Monday," the Los Angeles Times reports. "But a lawyer for the state's largest for-profit insurer argued that the patient, Ephram Nehme, was not sick enough to qualify for an exception to his policy's requirement that transplants be performed in Blue Cross-contracted hospitals in California.

23 Feb 2010

BD Biosciences initiates next-generation flow cytometer

BD Biosciences, a segment of BD, announced today the launch of the BD FACSAria™ III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.

From BD (Becton, Dickinson and Company) 23 Feb 2010

Cantimer, Advanced Instruments announce license and product development agreement

Cantimer, Inc., and Advanced Instruments, Inc. today jointly announced that the two companies had signed a license and product development agreement. Under the terms of the license agreement, Advanced Instruments received an exclusive license to Cantimer's unique sensor technology for select applications in the biotech market.

23 Feb 2010

AMA calls for fix to Medicare's doctor payments

With a sizable cut to Medicare physician payments taking effect in just one week, the American Medical Association is seeking clarity from Congress on its plan of action to stop the 21.2% reduction.

23 Feb 2010

Access Systems awarded $3.5M contract to support HHS FTS2001-Networx Transition Program Management Office

Access Systems, Inc. (ACCESS), an information technology (IT) solutions provider, has been awarded a $3.5M contract by GSA's National Capital Region to support the Department of Health and Human Services (HHS) FTS2001-Networx Transition Program Management Office. ACCESS and team partner, BCCP Consulting, LLC, will assist HHS to conduct Fair Opportunity for selecting the Networx vendors that will provide telecommunications and associated professional services to the HHS OPDIVs.

23 Feb 2010

Medtronic third-quarter revenues up by 10%

Medtronic, Inc. today reported financial results for the third quarter of fiscal year 2010, which ended January 29, 2010.

23 Feb 2010

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company’s common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.

23 Feb 2010

Medical News

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Findings suggest bitter melon extract may help in preventing breast cancer

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Government, with billions in loans, bets electronic medical records can improve care

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Blair talks about combating malaria in Nigeria, part of 3-nation African trip

Jobs bill missing Medicaid money for states, governors call for change

Timely treatment and rehabilitation key to proper healing

Elevated cerebrospinal fluid levels of P-tau231 may be an early diagnostic biomarker for Alzheimer's disease

EHSI: Health stocks gain after federal decision on payments

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

New Barts Cancer Research UK Centre launched

Trial for lawsuit against Anthem Blue Cross begins in California

BD Biosciences initiates next-generation flow cytometer

Cantimer, Advanced Instruments announce license and product development agreement

AMA calls for fix to Medicare's doctor payments

Access Systems awarded $3.5M contract to support HHS FTS2001-Networx Transition Program Management Office

Medtronic third-quarter revenues up by 10%

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News